Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function.

Division of Clinical Pharmacology and Experimental Therapeutics, Department of Biopharmaceutical Sciences, University of California at San Francisco, San Francisco, CA 94158, USA.
The Pharmacogenomics Journal (Impact Factor: 5.13). 02/2009; 9(2):127-36. DOI: 10.1038/tpj.2008.19
Source: PubMed

ABSTRACT hMATE1 (human multidrug and toxin compound extrusion-1; encoded by SLC47A1) is thought to have an important function in the renal and hepatic elimination of drugs, endogenous compounds and environmental toxins. The goals of this study were to identify genetic variants of hMATE1 and to determine their effects on hMATE1 transport function. We identified four synonymous and six nonsynonymous, coding region variants in DNA samples from 272 individuals (68 Caucasians, 68 African Americans, 68 Asian Americans and 68 Mexican Americans). The overall prevalence of hMATE1 nonsynonymous variants was relatively low with three singleton variants and three variants having allele frequencies > or =2% in a specific ethnic group. The nonsynonymous hMATE1 variants were constructed and stably transfected into HEK-293 cells. Uptake studies using four known hMATE1 substrates (paraquat, metformin, tetraethylammonium and oxaliplatin) were performed in cells transfected with hMATE1 reference or variants. We found that two singleton variants, G64D and V480M, produced a complete loss of function for all four tested substrates whereas three polymorphic variants (allele frequencies > or =2%), L125F, V338I and C497S, significantly altered the transport function in a substrate-dependent manner. Confocal microscopy studies were consistent with functional studies suggesting that the altered function of the variants was due to altered localization to the plasma membrane. These data suggest that nonsynonymous variants in hMATE1 may alter drug disposition and ultimately affect clinical drug response.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Intestinal transporters are crucial determinants in the oral absorption of drugs. We therefore studied mRNA expression (N=33) and absolute protein content (N=10) of clinically relevant transporters in healthy epithelium of the duodenum, proximal and distal jejunum and ileum and the ascending, transversal, descending and sigmoidal colon of six organ donors (24-54 years). In the small intestine, the abundance of nearly all studied proteins ranged between 0.2-1.6 pmol/mg with the exception of OCT3 (<0.1 pmol/mg) and PEPT1 (2.6-4.9 pmol/mg) which accounted for ~50% of all measured transporters. OATP1A2 was not detected in any intestinal segment. ABCB1, ABCG2, PEPT1 and ASBT were significantly higher abundant in jejunum/ileum than in colon. In contrast to this, ABCC2, ABCC3 and OCT3 expression was found to be highest in colon. Site-dependent expression was confirmed for ABCB1 and ASBT and significant correlations between mRNA and protein levels for ABCG2, ASBT, OCT3 and PEPT1 in the small intestine. Our data provide further physiological pieces in the puzzle required to predict intestinal drug absorption in man.
    Molecular Pharmaceutics 08/2014; · 4.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study was performed to identify genetic polymorphisms in multidrug and toxin extrusion 2-K (MATE2-K, SLC47A2), a proton/organic cation antiporter that plays a role in the transport of organic cations across the apical membrane in kidney epithelial cells into the urine, and to demonstrate their effects on MATE2-K functions in vitro. Four of the thirty single nucleotide polymorphisms (SNPs) we identified in three ethnic groups (Caucasian, African American, and Japanese) were novel [308C>G (P103R), c.487-8C>T, 818A>G (Y273C), and c.1018+14T>C]. The transport activities of the prototypical substrates, tetraethylammonium and metformin, for four nonsynonymous SNPs (P103R, P162L, G211V, and Y273C) were significantly different from those of the wild type. In particular, transport activity was higher in P103R than in the wild type, which is the first time elevated transport activity was demonstrated due to these coding SNPs. Kinetic analysis revealed that P103R had a higher Vmax value, while Y273C had a lower value than that in the wild type. Cell surface protein expression levels were higher for P103R than for the wild type, whereas Y273C expression was decreased. Immunofluorescence analysis revealed that the P103R protein was localized to the plasma membrane, whereas Y273C showed cytoplasmic localization. Therefore, the difference in transport activities between P103R and Y273C variants was suggested to be responsible for the different protein expression levels observed at the plasma membrane. Four nonsynonymous SNPs in this study showed relatively low allelic frequencies (0.5 to 2.1%), but these were associated with markedly reduced or increased MATE2-K function.
    Drug metabolism and disposition: the biological fate of chemicals 07/2014; · 3.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic kidney disease (CKD) is a complex disorder with a strong genetic component. A number of common sequence variants have been found to associate with serum creatinine (SCr), estimated glomerular filtration rate (eGFR) and/or CKD. We imputed 24 million single nucleotide polymorphisms and insertions/deletions identified by whole-genome sequencing of 2,230 Icelanders into 81,656 chip-typed individuals and 112,630 relatives of genotyped individuals over the age of 18 with SCr measurements. The large set of sequenced individuals allowed accurate imputation of variants to a minor allele frequency of 0.1%. We tested the imputed variants for association with SCr. In addition to replicating established loci, we discovered missense and loss of function variants associating with SCr in three solute carriers (SLC6A19, SLC25A45, SLC47A1) and two E3 ubiquitin ligases (RNF186, RNF128). All the variants are within coding sequences and all but one are rare (minor allele frequency <2%) with SCr effects between 0.085 and 0.129 standard deviations (SD). These rare variants have a larger effect on SCr than previously reported common variants, explaining 0.5% of the variability of SCr in Icelanders in addition to the 1% already accounted for. We tested the 5 variants associating with SCr for association with CKD in an Icelandic sample of 15,594 cases and 291,428 controls. Three of the variants also associated with CKD. These variants may either affect kidney function or creatinine synthesis and excretion. Of note were four mutations in SLC6A19 that associate with reduced SCr, three of which have been shown to cause Hartnup disease.
    Human Molecular Genetics 07/2014; · 6.68 Impact Factor

Full-text (2 Sources)

Available from
Sep 6, 2014